
People with progressive multiple sclerosis may have a better option for treatment thanks to a new drug being tested in a at the .
The study鈥檚 principal investigator for the clinical trial is . He鈥檚 been conducting trials with the drug to slow atrophy in patients.
There are currently no effective therapies, but Fox says he staying 鈥渃autiously optimistic.鈥�
鈥淵ou might imagine patients want therapies now;they are struggling with their progressive MS now and they don鈥檛 want to wait five years for a drug to be developed. So that鈥檚 one of our big challenges, to develop drugs faster and more efficiently so we can bring them to patients quickly,鈥� said Dr. Fox.
The drug trial is in phase two with the main outcome showing that ibudilast did slow the progression of atrophy compared to placebos. However the drug still must go through a final phase of trials to obtain approval.
Copyright 2021 WKSU. To see more, visit .